GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teligent Inc (OTCPK:TLGTQ) » Definitions » YoY Rev. per Sh. Growth

Teligent (Teligent) YoY Rev. per Sh. Growth : -95.39% (As of Jun. 2021)


View and export this data going back to 1997. Start your Free Trial

What is Teligent YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Teligent's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2021 was -95.39%.

Teligent's Revenue per Share for the three months ended in Jun. 2021 was $0.11.


Teligent YoY Rev. per Sh. Growth Historical Data

The historical data trend for Teligent's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teligent YoY Rev. per Sh. Growth Chart

Teligent Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.03 -4.89 8.86 -0.42 -55.50

Teligent Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.68 -31.26 -84.59 -89.15 -95.39

Teligent YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Teligent's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2020 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2020 )
=(Revenue per Share (A: Dec. 2020 )-Revenue per Share (A: Dec. 2019 ))/ | Revenue per Share (A: Dec. 2019 ) |
=(5.446-12.239)/ | 12.239 |
=-55.50 %

Teligent's YoY Rev. per Sh. Growth for the quarter that ended in Jun. 2021 is calculated as:

YoY Rev. per Sh. Growth (Q: Jun. 2021 )
=(Revenue per Share (Q: Jun. 2021 )-Revenue per Share (Q: Jun. 2020 )) / | Revenue per Share (Q: Jun. 2020 )) |
=(0.112-2.429)/ | 2.429 |
=-95.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Teligent YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Teligent's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Teligent (Teligent) Business Description

Traded in Other Exchanges
N/A
Address
105 Lincoln Avenue, Buena, NJ, USA, 08310
Teligent Inc is a specialty generic pharmaceutical company. Teligent develops, manufactures, and sells (under its own label) topical, injectable, complex, and ophthalmic pharmaceutical products in the U.S. and Canada. The product portfolio consists of hospital-based sterile injectable products and topical products (creams like Synalar and Spectazole; lotions like Kenalog; ointments like Topicort and Kenalog; and topical solutions like Pennsaid and Xylocaine). The company also offers services to the pharmaceutical, over-the-counter, and cosmetic markets.
Executives
Joseph Benesch officer: VP, Controller, PAO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
Alyssa Lozynski officer: Interim CFO C/O TELIGENT, INC. 105 LINCOLN AVENUE BUENA NJ 08310
William S Marth director 236 GROVE STREET, WELLESLEY MA 02482
Philip K Yachmetz officer: EVP, Chief Legal Off, Corp Sec 501 LAFAYETTE AVE WYCKOFF NJ 07481
R Carter Pate director 5739 WORTHAM LANE, DALLAS TX 75252
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Carole Ben-maimon director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656
Sabatino Thomas J Jr director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
John E Celentano director C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Steven H Koehler director C/O THE MEDICINES CO, 5 SYLVAN WAY, PARSIPPANY NJ 07054
Keith James officer: Prin Acct Officer Controller 105 LINCOLN AVENUE BUENA NJ 08310
Life Sciences Opportunities Fund Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Donald V Weir 10 percent owner SANDERS MORRIS HARRIS, 600 TRAVIS, HOUSTON TX 77002
Timothy B. Sawyer officer: CEO C/O TELIGENT, INC. 105 LINCOLN AVENUE BUENA NJ 08310